Analysis of CD34+ cell collection using two mobilization regimens for newly diagnosed multiple myeloma patients reveals the separate impact of mobilization and collection variables
Article first published online: 18 DEC 2013
© 2013 Wiley Periodicals, Inc.
Journal of Clinical Apheresis
Volume 29, Issue 5, pages 251–255, October 2014
How to Cite
Abuabdou, A., Rosenbaum, E. R., Usmani, S. Z., Barlogie, B. and Cottler-Fox, M. (2014), Analysis of CD34+ cell collection using two mobilization regimens for newly diagnosed multiple myeloma patients reveals the separate impact of mobilization and collection variables. J. Clin. Apheresis, 29: 251–255. doi: 10.1002/jca.21313
- Issue published online: 12 OCT 2014
- Article first published online: 18 DEC 2013
- Manuscript Accepted: 27 NOV 2013
- Manuscript Revised: 26 OCT 2013
- Manuscript Received: 28 JUN 2012
- National Cancer Institute, National Institutes of Health. Grant Number: CA055819
Mobilization regimens for CD34+ cells have generally been judged successful based on the number of cells collected without evaluating mobilization separately from collection. Using retrospective data for patients who collected CD34+ cells on Total Therapy protocols 3a/3b (VTD-PACE) and Total Therapy 4/5 using a novel regimen that added low dose melphalan to VTD-PACE (MVTD-PACE), we analyzed mobilization and collection variables separately. A significant difference favoring MVDT-PACE was found in mean CD34+ cells/µL on day 2 of collection and in mean ratio of CD34+ cells/µL on day 2 to day 1. However, because apheresis variables and growth factor dose during collection were manipulated to optimize individual collections, the two regimens were not significantly different when the mean total CD34+ cells ×106/kg collected was compared. Thus, when evaluating a chemotherapy regimen or new growth factor for mobilization, it is important to realize that total CD34+ cells collected is dependent on both mobilization and collection variables. J. Clin. Apheresis 29:251–255, 2014. © 2013 Wiley Periodicals, Inc.